Despite compelling data from trials like PATINA, some patients with ER+/HER2+ breast cancer refuse maintenance endocrine therapy due to side effects. This highlights a real-world gap between clinical trial evidence and patient adherence, forcing oncologists to navigate patient preferences against optimal treatment protocols.

Depression is highly prevalent in the advanced endometrial cancer population, affecting up to 50% of patients. It is often missed by clinicians and unreported by patients, despite its significant impact on treatment adherence and mortality.

Current Quality of Life (QoL) assessments in cancer trials fail to capture severe, long-term toxicities. They are designed for short-term effects and data collection often ceases after a patient experiences a life-changing adverse event, thus painting an inaccurately rosy picture of a drug's tolerability.

Simple text reminders for medication adherence are common. The real opportunity is using two-way, AI-powered texting to create conversations that uncover the specific reasons (out of over 250 identified) why a patient might stop taking their medication, allowing for timely and personalized interventions.

The enzalutamide arms saw discontinuation rates of 20-25% due to adverse events. This high rate reflects a different risk calculation for patients who feel healthy and are asymptomatic. Unlike in advanced disease where patients tolerate more toxicity, this population has a very low threshold for side effects, making early intervention a significant trade-off.

In clinical trials, patients "vote with their feet." High rates of discontinuing an optional (adjuvant) phase of treatment provide a clearer, real-world signal of toxicity and their personal risk-benefit analysis than formal Quality of Life surveys. Their actions speak louder than their written responses.

Healthcare systems invest heavily in diagnosis but then abandon patients once a prescription is handed over. This "disconnection point" leads to medication non-adherence and confusion, as the patient's actual healing journey is just beginning and requires ongoing support.

Oncology research is moving beyond standard quality-of-life metrics to study 'decision regret' and toxicity perception after adjuvant therapy is completed. This novel approach better captures the long-term psychological impact on patients, whose perspectives often change dramatically months or years after their initial treatment decision.

The most significant, lasting effects of treatment toxicities on quality of life often become most apparent *after* therapy has concluded. Clinical trials that stop collecting data shortly after treatment completion miss this crucial long-term impact, underestimating the true burden of side effects.